Sep 06,2023

Flatiron Health enters new five-year research collaboration with FDA on real-world data

Flatiron Health today announced its renewed collaboration with the Oncology Center of Excellence (OCE) of the United States Food and Drug Administration (FDA) to jointly develop and implement specific research projects to advance the use of real-world data (RWD) and explore the potential strengths and limitations of using real-world evidence (RWE) for regulatory purposes. The partnership will specifically evaluate RWD study designs and analytic methods through the collaborative development of priority, clinically meaningful research questions regarding care, treatment, and outcomes of patients with cancer.

COLLABORATION PARTNERSHIP

#r&d

#rwd

#rwe

View Analyst & Ambassador Comments
Go to original news
Oct 03,2023

Enriching access to multimodal data insights with COTA Connect

COTA is introducing COTA Connect: a powerful new capability to link data with a variety of different supplemental data sources, including linking COTA’s robust real-world clinical data to claims, imaging, socioeconomic data, and more. COTA will provide the tokens that allow linkage to a claims data source, creating a more comprehensive view of patients’ care. This increases granularity of understanding around individuals and populations of interest. According to the press release, COTA can also provide analytical services to analyze the merged dataset and answer relevant research questions.

PRODUCT

#rwd

#rwe

View Analyst & Ambassador Comments
Go to original news
Sep 27,2023

Aitia and Pancreatic Cancer Action Network Partner to Transform De-Identified Multi-Omic Patient Data into Digital Twins to Drive New Discoveries and Improve Patient Outcomes

Aitia today announced a collaboration with the Pancreatic Cancer Action Network (PanCAN), a leading nonprofit in the fight against pancreatic cancer. This strategic collaboration marks a significant milestone for Aitia, reinforcing its commitment to expanding its impact and accelerating the discovery and development of new drugs in pancreatic cancer. Utilizing PanCAN’s health data platform, SPARK, Aitia will integrate PanCAN de-identified human multi-omic data to create Gemini Digital Twins, that will serve a wide range of applications, including the discovery of novel targets and biomarkers, simulation of drug candidates, identification of ideal patient subpopulations for clinical trials, and the determination of optimal drug combinations.

COLLABORATION PARTNERSHIP

#data & technology

#rwd

#ai/software

View Analyst & Ambassador Comments
Go to original news
Sep 06,2023

Veracyte and Gustave Roussy Announce Collaboration to Help Biopharmaceutical Companies Accelerate Development of Novel Cancer Therapies

Veracyte, Inc., a global diagnostics company, and Gustave Roussy, a leading cancer center worldwide, announced today that they have entered into a collaboration to bring together their respective capabilities to provide novel insights into the underlying biology of metastatic tumors, which may help biopharmaceutical companies accelerate development of new cancer therapies. Through the partnership, Gustave Roussy’s Department of Therapeutic Innovation and Early Clinical Trials (DITEP) will provide metastatic tumor samples and data for multiple cancer indications that are derived from its major innovative research projects, particularly for new immunotherapies. Veracyte will combine these assets with its multi-omics testing and machine learning capabilities to create a Veracyte Biopharma Atlas reference database of genomic and immunomic biomarkers. The company will then leverage this deep characterization of each tumor’s biology, particularly its immune contexture, to derive further insights about tumors that are more likely to respond to a particular therapy.

COLLABORATION PARTNERSHIP

#data & technology

#rwd

#ml

View Analyst & Ambassador Comments
Go to original news
Jul 26,2023

AI Empowers Researchers to Bring Precision Medicine to Post-stroke Speech and Cognitive Rehabilitation

Constant Therapy Health, a next generation digital health company, today announced that the organization is empowering Boston University Center for Brain Recovery and The University of Texas at Austin neuroscientists, data engineers and computational scientists with the AI-driven, real-world data needed to bring precision medicine to post-stroke speech, language and cognitive rehabilitation. Researchers will employ the company’s proprietary data, which is based on more than 230 million speech and cognitive therapy exercises completed by 100,000+ de-identified patients, to conduct real-world, evidence-based studies.

#rwd

View Analyst & Ambassador Comments
Go to original news
Aug 23,2023

How real-world data is enhancing our understanding of lung cancer recurrence

A collaborative team from COTA and AstraZeneca used curated RWD to investigate factors affecting disease-free survival and recurrence patterns in early-stage non-small cell lung cancer (NSCLC) patients. The researchers examined patterns of care, disease-free survival, and patient characteristics using real-world data from over 700 early-stage NSCLC patients diagnosed between 2013 and 2018. They found that patients with more advanced disease stages, genetic mutations (EGFRm positive), and those who only had surgical resection had shorter disease-free survival times. Distant/metastatic recurrence was common among all patients. The study confirmed that disease stage at diagnosis influences disease-free survival and supported the idea that adjuvant therapies improve disease-free survival compared to surgery alone.

COLLABORATION PARTNERSHIP

#data & technology

#rwd

View Analyst & Ambassador Comments
Go to original news
Aug 22,2023

Tempus Welcomes UNC Lineberger Comprehensive Cancer Center to Tempus+ Community

Tempus, a leader in artificial intelligence and precision medicine, today announced that the University of North Carolina (UNC) Lineberger Comprehensive Cancer Center has joined Tempus+, a proprietary program that powers collaborative precision oncology research through the use of real-world data. The Tempus+ community of researchers already includes over 30 medical centers that are leveraging the program to advance its research. Tempus+ is creating a sustainable and secure infrastructure to collect and analyze the data required to foster research that can inform the future of clinical care. Researchers at UNC Lineberger now have access to Tempus’ library of more than six million de-identified research records through the company’s data analytics platform, Lens, to identify patterns and insights, define and test their hypotheses, and eventually investigate and potentially publish their research.

COLLABORATION PARTNERSHIP

#institution

#rwd

View Analyst & Ambassador Comments
Go to original news
Aug 21,2023

PicnicHealth partners with AstraZeneca to advance cancer datasets

Health technology company PicnicHealth announced it is moving into the oncology space and teaming up with AstraZeneca to build a registry to generate real-world data on breast cancer. The company says it will work with people living with cancer to collect and structure their medical records data to advance oncology research using robust datasets. Additionally, the California-based company announced a multiyear partnership with biopharmaceutical giant AstraZeneca to create a registry to generate longitudinal real-world data from consenting U.S. patients diagnosed with stage 1 to stage 3 breast cancer. The registry, which patients can currently enroll in, will organize their medical records into a centralized portal and allow patients to contribute their de-identified data to breast cancer research.

COLLABORATION PARTNERSHIP

#data & technology

#rwd

View Analyst & Ambassador Comments
Go to original news
Mar 28,2019

Bristol-Myers Squibb and ConcertAI Announce Strategic Agreement to Broaden Uses of Real-World Evidence and Accelerate Precision Oncology Innovations

Bristol-Myers Squibb and ConcertAI today announced a multi-year strategic agreement that will cover a diverse range of cancers, integrate multiple data sources, and apply AI and machine learning to accelerate clinical trials, enable robust protocol design and generate insights for precision treatment and improved patient outcomes. Bristol-Myers Squibb will use ConcertAI’s Real-World Data and novel AI insights platform, eurekaHealth™, to accelerate insights through novel health economic outcomes and clinical development synthetic control arm studies. With this agreement, the companies will advance the use of RWE for regulatory purposes, validate clinical application of AI solutions and execute clinical studies to advance patient care.

COLLABORATION PARTNERSHIP

#data & technology

#rwd

#ai/software

View Analyst & Ambassador Comments
Go to original news
Jul 27,2023

PathAI Launches its AI-Powered PathExplore Data Access Program For Academic Researchers

PathAI, a global leader in AI-powered pathology, today announced it has applied its PathExplore panel of human interpretable features (HIFs) on publicly available samples from The Cancer Genome Atlas (TCGA), a comprehensive resource of oncology data containing genomic and outcomes data, along with associated H&E whole-slide images (WSIs). PathAI will make the HIFs from eight TCGA cancer types available for free as a data access program for academic researchers to perform independent research to support their own investigations. Powered by artificial intelligence, PathExplore spatially characterizes the TME with single-cell resolution, giving researchers the ability to unlock insights on patient response, drug pathways, and potential novel biomarkers.

PRODUCT

#rwd

#ai/software

View Analyst & Ambassador Comments
Go to original news
Subscribe to RWD